The science, read straight
Thymosin Alpha-1 Research: Mechanism, Trials, and Where the Evidence Stops
Each finding logged to its study, the strong signals and the null one held in the same light.
Before the details
Thymosin Alpha-1 research spans biochemistry, immunology, and four decades of clinical trials, so here is the map before the territory. The peptide was isolated and sequenced in 1977. We understand fairly well how it works: it nudges the immune system's sentinel cells to mature and present threats, which sharpens the T-cell response, while a second arm keeps that response from running away. The clinical record is broad but uneven. It is strongest in long-term hepatitis B, mixed in COVID-19, and — importantly — negative in the single largest sepsis trial. Below, each claim is tied to a numbered study you can check on the references page. Where the evidence is thin or conflicting, this page says so rather than smoothing it over. Doses, when they appear, are reported only as what was studied in a named population by a named route — never as guidance.
Thymosin alpha-1
Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated polypeptide first isolated from calf thymus as part of "thymosin fraction 5," with Goldstein and colleagues purifying it and determining its complete sequence in 1977 [1]. It is highly acidic, carries no aromatic residues and no disulfide bonds, and is cleaved in the body from a 113-amino-acid precursor, prothymosin alpha [1]. The N-terminal acetyl group is essential for activity — the synthetic drug thymalfasin is sequence-identical [4]. This is the molecule the rest of the page is about; everything downstream traces back to this structure.
Mechanism — the dendritic-cell switch
The peptide's central action is on dendritic cells. Working through Toll-like receptors TLR9 and TLR2, it drives dendritic-cell maturation, IL-12 production, and antigen presentation, which matures T-cells and polarizes them toward Th1 immunity (IFN-γ, IL-2) [5]. A landmark study showed it activates dendritic-cell tryptophan catabolism through IDO — an effect that required TLR9 and type I interferon receptor signalling and produced IL-10 plus regulatory T-cells, establishing a tolerogenic frame around the Th1 priming [5]. In severe disease it expands cytotoxic CD8+ T-cells and reverses T-cell exhaustion, lowering PD-1 and Tim-3 [6], and it restores monocyte HLA-DR in immune paralysis [2]. The dual signature — lift the suppressed, restrain the inflamed — falls directly out of this mechanism.
Thymosin alpha 1 peptide
As a thymosin alpha 1 peptide drug, its pharmacology is well characterized. After subcutaneous injection in humans the serum half-life is roughly 2 hours, peak concentration (30-80 mcg/L) arrives within 1-2 hours, the volume of distribution (~30-40 L) matches extracellular-fluid distribution, and blood levels return toward baseline within 24 hours [8]. A mouse biodistribution study found a rapid serum rise within two minutes lasting about two hours, high uptake in thymus, spleen, and lungs, and rapid renal excretion as the major clearance route [10]. Formulation work has pushed toward sustained release: PLGA microspheres achieved roughly 90% cumulative release over a month in vitro and raised the CD4+/CD8+ ratio in immunosuppressed rats [11].
Ta1 peptide
The Ta1 peptide abbreviation (Tα1) is the same molecule under its shorthand, and US clinical interest in it is not new — Goldstein and colleagues summarized the status of United States thymosin trials for immune and neuroendocrine modulation as far back as 1990 [14]. A pharmacy monograph later consolidated the dosing, pharmacokinetics, and safety reference for the development program [9]. The shorthand shows up constantly in research-use communities; it always means the 28-amino-acid immune peptide on this page, never a different compound.
Thymalfasin
Thymalfasin is the International Nonproprietary Name for the synthetic, sequence-identical form of Thymosin Alpha-1 used in essentially every modern trial [4]. The synthetic peptide is approved as a drug in roughly 35 countries — for chronic hepatitis B and as an immune adjuvant — and is usually well tolerated, with local injection-site irritation the most common adverse effect [4]. It is the generic name a reader will meet in the trial literature; the foreign brand name is not used on this site by design.
Thymosin alpha 1 covid
The thymosin alpha 1 covid record is genuinely mixed, and the honesty matters. In a retrospective review of 76 patients with severe COVID-19, treatment was associated with significantly reduced mortality (11.11% versus 30.00%) and reversed T-cell exhaustion, restoring T-cell numbers in patients with severe lymphocytopenia [6]. An in-vitro study added mechanism: in SARS-CoV-2-stimulated immune cells the peptide reduced TNF-α, IL-6, and IL-8 while raising IL-10 [13]. But a 2022 systematic review of roughly 5,300 patients found no statistically significant overall mortality benefit — so the cohort signals are not confirmed at the level of pooled, controlled evidence.
The hepatitis record — the strongest signal
Where Thymosin Alpha-1 looks most convincing is chronic viral hepatitis. A meta-analysis of eight trials (583 patients) comparing lamivudine plus the peptide against lamivudine alone found the combination significantly superior for hepatitis B e-antigen seroconversion (45.1% versus 15.2%) and virological response, and the peptide plus entecavir outperformed entecavir alone in cirrhotic patients [12]. This is the indication where four decades of international data are most consistent — and the reason thymalfasin carries marketing approval abroad.
The sepsis story — and the null trial
Sepsis is where the record turns cautionary. The earlier multicentre ETASS trial of 361 patients reported 28-day mortality of 26.0% with the peptide versus 35.0% in controls — an absolute reduction of about nine points that did not reach conventional significance [2]. The definitive test came in 2025: the phase-3, double-blind, placebo-controlled TESTS trial enrolled 1,106 adults across 22 centres and found no significant difference in 28-day mortality (23.4% versus 24.1%; hazard ratio 0.99, P=0.93) [3]. The largest, most rigorous sepsis trial to date was null — which tempers the earlier positive but lower-quality results and is the single most important caveat on this page.
Thymosin alpha 1 vs thymosin beta 4
The thymosin alpha 1 vs thymosin beta 4 distinction is the one this site most insists on, because the two are constantly confused. They share a family name and almost nothing else. Thymosin Alpha-1 is a 28-amino-acid acetylated immune modulator that acts on dendritic cells and T-cells [1][5]. Thymosin beta-4 (sold and discussed as TB-500) is a different 43-amino-acid actin-binding peptide studied for tissue repair and motility — a different sequence, a different size, a different mechanism, and a different use. TB-500 is the one on the prohibited-substance lists; Thymosin Alpha-1 is not it. Two further neighbors round out the confusion: thymulin (FTS), a zinc-dependent nonapeptide, and thymopentin (TP-5), a pentapeptide — both distinct molecules, neither interchangeable with this one. The Thymosin Alpha-1 references page lists the primary sources for each claim here.